FIELD: biotechnology, immunology.
SUBSTANCE: disclosed are method for selective apoptosis inducing in target DR5 expressing cells, method for inhibiting of said target cell proliferation, method for treatment of individual suffering from inflammation or autoimmune disease. Each method includes application of therapeutically effective amount of antibody in solvent form which is specific to DR5 TRAIL-receptor followed by affect to cell with therapeutic amount of one or therapeutic agents. Antibody in concentration of 1 mug/ml has apoptosis inducing activity in target cells expressing DR5 both in vivo and in vitro. Disclosed is composition for selective apoptosis inducing in target DR5 expressing cells based on abovementioned antibody and therapeutic amount of one or more therapeutic agents.
EFFECT: effective composition for tumor therapy.
80 cl, 94 dwg, 6 tbl, 30 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| APOPTOTIC Apo2L/TRAIL SENSITIVITY BY TESTING GalNac-T14 EXPRESSION IN CELLS/TISSUES | 2006 |
|
RU2416097C2 |
| ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| ANALYSES AND METHODS USING BIOMARKERS | 2005 |
|
RU2410438C2 |
| METHOD FOR MAKING MUTANT HUMAN TRAIL PROTEIN | 2009 |
|
RU2405038C1 |
| ANALYSES AND METHODS WITH APPLICATION OF BIOMARKERS | 2005 |
|
RU2431676C2 |
| DEGRADED ANTIBODY AS TPO AGONIST | 2001 |
|
RU2287534C2 |
| MODIFIED ANTAGONISTIC ANTIBODY | 2001 |
|
RU2295537C2 |
